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Effect of Long-Term Oral Bisphosphonates on Implant
Wound Healing: Literature Review and a Case Report
Hom-Lay Wang,* Daniel Weber,* and Laurie K. McCauley*†
Background: Bisphosphonates suppress osteo-
clast activity, and their intravenous use has been
reported in hundreds of cases to be associated with
osteonecrosis in the jaw. Little is known of the risks as-
sociated with long-term use of oral bisphosphonates
despite their use for >10 years by an oral mode of de-
livery for the treatment of osteopenia, osteoporosis,
and Paget’s disease of bone. The purpose of this report
is to review the literature associated with bisphos-
phonate use that could impact bone healing and to re-
port a case of bone necrosis in a patient on long-term
oral bisphosphonates.
Methods: A Medline search was carried out to find
relevant articles from both medical and dental litera-
ture between 1960 and 2006. A patient, who had
been taking an oral bisphosphonate for >10 years, de-
veloped unexplained clinical signs of bone necrosis af-
ter routine dental implant placement. This case was
followed, documented, and the treatment of the osteo-
necrosis described.
Results: A summary of how bisphosphonates
may play a role in wound healing is presented.
The compromised healing noted in a patient, who
was under long-term oral bisphosphonate use, was
successfully treated with systemic antibiotics, local
microbial mouthrinse, and aggressive defect man-
agement (detoxification and mixture of bone graft
and tetracycline).
Conclusions: This case suggests that patients un-
der long-term oral bisphosphonate use should be
treated with caution. Well-controlled, prospective clini-
cal trials on the effect of oral bisphosphonates on bone
are warranted to determine which patients may be
at risk for such complications. J Periodontol 2007;
78:584-594.
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B
isphosphonates are synthetic biochemical
modifiers of bone resorption. This class of
drugs has proved to be highly effective in
the treatment of osteoporosis, Paget’s disease, and
skeletal complications of bone metastases. Initial
work with bisphosphonates can be traced back to the
pioneering work of Fleisch et al.1 Even before evi-
dence of biologic activity in vivo, bisphosphonates
were used for many industrial applications because
of their ability to prevent calcium carbonate precip-
itation. The early work that formed the basis for
bisphosphonate development stemmed from find-
ings that inorganic pyrophosphate from serum and
urine was able to inhibit the precipitation of calcium
in vitro.2 Further work found that pyrophosphates
were able to prevent calcium phosphate dissolution
in vitro, and in vivo applications proved valuable in
the prevention of ectopic calcifications, but there
was little effect on bone formation or resorption.3
Francis et al.4 and Fleisch et al.5 proceeded to ex-
plore various chemical formulations of pyrophos-
phates to discover an analogue with potent effects on
mineralization and resorption.
The action of bisphosphonates depends on the
drug’s chemical structure. The two main categories of
bisphosphonates are the non-nitrogen and nitrogen-
containing bisphosphonates.6 Both forms of bisphos-
phonates are taken up into mineralized structures and
released during resorption. On release, bisphospho-
nates are internalized by osteoclasts. The non-nitrogen
bisphosphonates are metabolized by osteoclasts into
cytotoxic analogues of adenosine triphosphate.7 These
analogues build up and lead to osteoclast apoptosis or
cell death. In addition, nitrogen-containing bisphos-
phonates are taken up by osteoclasts during resorp-
tion and disrupt the mevalonate pathway.6,8-10
The mevalonate pathway was identified by Katsuki
and Bloch11 and Lynen12 as the pathway that leads to
the synthesis of cholesterol. Three molecules of cyto-
solic acetyl succinyl-coenzyme (CoA), transported
from mitochondria, condense to form 3-hydroxy-3-
methylglutaryl CoA (HMG CoA). HMG-CoA reductase
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reduces HMG-CoA into mevalonate, the first com-
mitted step in cholesterol synthesis.13 Cholesterol-
lowering drugs, statins, act directly on this step and
disrupt the reduction of HMG-CoA into mevalonate.14
Devoid of any interference, mevalonate proceeds
through phosphorylations and decarboxylation to be-
come isopentenyl pyrophosphate. Isopentenyl pyro-
phosphate condenses with its isomer, dimethylallyl
pyrophosphate, to form geranyl pyrophosphate.
Geranyl pyrophosphate further condenses with an-
other isopentenyl pyrophosphate by the enzymatic
action of farnesyl diphosphonate synthase to form
farnesyl pyrophosphate.Nitrogen-containingbisphos-
phonates inhibit this step in the mevalonate path-
way.15 Inhibition of the mevalonate pathway prevents
many post-translational modifications, including those
needed to adequately promote intracellular vesicular
transport.16 Without proper transport, osteoclasts are
unable to form a ruffled border, which is essential for
bone resorption.17
The inhibition of the mevalonate pathway at the
level of farnesyl pyrophosphate formation produces
similar effects as non–nitrogen-containing bisphos-
phonates, in particular the formation of apoptotic
metabolites.15 Inhibition at the level of the farnesyl py-
rophosphate formation results in a build-up of isopen-
tenyl diphosphonate. Isopentenyl diphosphonate can
be metabolized into Appi, an intracellular adenosine
triphosphate analogue.18 Appi has been shown to
produce apoptosis similar to that of the clodronate
metabolite, adenosine 59-(b, g-dichloromethylene)
triphosphate (AppCCl2p).19,20
The chemical composition of the bisphosphonate
determines the drug’s potency. All bisphosphonates
contain two carbon-phosphate bonds (C-P), com-
prised primarily of a central core of P-C-P. The addi-
tion of an amine group to the end of a side chain
increases the drug’s potency.3 Table 1 presents a list
of bisphosphonates and their route of administration.
A large proportion of the drug is rapidly taken up by
the skeleton after administration. Fifty percent of
the drug is excreted by the kidneys without any me-
tabolism, and the remainder is sequestered in the
bone. The half-life of bisphosphonates ranges from
months to years, with reports suggesting that bisphos-
phonates can still be found in bone over a decade after
their administration. However, once new bone is de-
posited over bisphosphonate-containing layers, the
effect on osteoclasts is diminished.10
Early bisphosphonates, such as etidronate and
clodronate, have a narrow therapeutic window; large
doses were required to achieve the desired resorption
inhibition.21 Etidronate and clodronate must be in-
fused over a lengthy period of time with careful mon-
itoring of serum creatinine; yet, even with careful
monitoring, both have been associated with acute re-
nal failure.22 The development of nitrogen-containing
bisphosphonates allowed for the delivery of bisphos-
phonates that conveyed nearly 10- to 100-fold in-
creases in potency compared to etidronate and
clodronate,23 but did not require the same quantity
of drug or lengthy infusion times. The more potent bis-
phosphonates have become a more convenient and
highly effective treatment option.
Bisphosphonates are administered either by intra-
venous (IV) infusion or oral administration. Either route
of delivery has been shown to be effective clinically,
but both have their associated risks.21 Bisphospho-
nate delivery by IV infusion has been associated with
adverse renal function, but this has been seen primar-
ily with higher infusion rates and increased dos-
ages.24,25 The oral administration of bisphosphonates
has not been found to be as deleterious to renal func-
tion, it but has been associated with adverse gastro-
intestinal events, such as esophagitis, mucositis, and
nausea.26 The biggest concern with oral administra-
tion is the rate of non-compliance and the subsequent
decrease in clinical effectiveness of the drug.27,28
Therefore, IV bisphosphonate delivery has been used
extensively for the treatment of such conditions as
breast, prostate, and lung cancer; plasma cell dyscra-
sias; and other malignant bone diseases, all of which
require strict drug therapy compliance.21,29
Recently, retrospective reports have been pub-




Generic Name Brand Name Nitrogen
Delivery
Route
Zoledronic acid* Zometa + IV
Pamidronate† Aredia + IV
Etidronate‡ Didronel - IV
Clodronate§ Bonefos - IV/oral
Ibandronatek Bondronat or Boniva + IV/oral
Tiludronate¶ Skelid - Oral
Risedronate# Actonel + Oral
Alendronate** Fosamax + Oral
* Zometa, Novartis Pharmaceuticals, New York, NY.
† Aredia, Novartis Pharmaceuticals.
‡ Didronel, Procter & Gamble Pharmaceutical, Cincinnati, OH.
§ Bonefos, Aventis Pharmaceuticals, Bridgewater, NJ.
k Boniva, Roche Pharmaceutical, Nutley, NJ.
¶ Skelid, Sanofi Pharmaceuticals, New York, NY.
# Actonel, Procter & Gamble Pharmaceutical.
** Fosamax, Merck, Whitehouse Station, NJ.
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bisphosphonate therapyandosteonecrosisof theman-
dible and maxillae. In2003,Marx30 published anarticle
concerning avascular necrosis of the jaws associated
with 36 patients taking IV bisphosphonates. Twenty-
four of these patients were on IV pamidronate, six had
started with pamidronate and were currently taking zo-
ledronate, and the final six were taking only zoledro-
nate. Twenty-eight of these patients had received
tooth extractions, whereas the other eight spontane-
ously developed lesions. Treatment consisted of
systemic antibiotics and chlorhexidine 0.12% mouth-
rinse with debridement as necessary. A more recent
report31 from this group included 119 patients; most
but not all were on IV bisphosphonates and a few were
under treatment for osteoporosis. The incidence of
periodontal disease in the overall population was high
(84%), nearly 38% of bone exposures were post–tooth
extraction, and a small percentage (3.4%) was associ-
ated with dental implant placement. This group31 was
effective in obtaining pain control in most patients
using antibiotics and a chlorhexidine mouthrinse but
reported that the exposed bone often remains.
Migliorati32 reported avascular bone necrosis in five
patients taking pamidronate or zoledronic acid. Three
of the cases involved the mylohyoid plate and two in-
volved previous extraction sites. Both hyperbaric oxy-
gen and surgical treatment proved to be ineffective.
Periodic treatment of debridement, bone trimming,
or antibacterial measures were required. Ruggiero
et al.33 reported 63 cases of ‘‘osteonecrosis of the
jaws.’’ These patients were also taking pamidronate or
zoledronic acid, but were not limited to only these IV
bisphosphonates; a few of the patients were taking
alendronate, an oral bisphosphonate. Treatment of
these patients involved far more advanced surgical
interventions, from sequestrectomy to partial or total
maxillectomy or mandibulectomy. A retrospective
analysis of 22 patients with multiple myeloma and IV
bisphosphonates use found a history of tooth extrac-
tion and age at diagnosis of the multiple myeloma
to be significantly associated with the occurrence
of osteonecrosis of the jaw.34 In another recent ar-
ticle, Hellstein and Marek35 reported 20 cases of
bisphosphonate-associated osteonecrosis. Histology
was performed for one of the cases. The histology re-
vealed minimal presence of Howship’s lacunae, con-
gested venules, and bacterial infiltrate within the
deep trabeculae. Histologic analyses have also re-
vealed microbiota of the Actinomyces species to be
highly associated with areas of osteonecrosis in the
jaw of patients.36 Two recent reviews37,38 have begun
to assimilate findings from the rapidly accumulating
case reports of bisphosphonate-associated osteo-
necrosis of the jaws, but there continues to be a lack
of knowledge regarding the impact of bisphosphonate
on normal healing in the oral cavity.
Oral alendronate‡ is a drug marketed for the treat-
ment of osteoporosis (10 mg/day or 70 mg/week) and
Paget’s disease (40 mg/day for 6 months). The mech-
anism of action involves a process called prenylation,
which directs the formation of the osteoclast-ruffled
border. This process is the covalent modification with
lipids of guanosine triphosphatase (GTPase) signal-
ing proteins. The modification allows the attachment
of proteins to the cell membrane, creating the ruffled
border. Bisphosphonates bound to bone are released
and taken up by osteoclasts during bone resorption.
The bisphosphonates taken up into the cell are thought
to block the signals that organize the ruffled border.
The exact mechanism is still not understood.39 Another
nitrogen-containing bisphosphonate, ibandronate,§
has recently been released on the market offering a
once-monthly oral dosing regimen. Studies have
found equivalent effectiveness of once-monthly dos-
ing (single 150-mg dose) of ibandronate compared
to daily (2.5-mg dose) ibandronate dosing.40 This
new dosing regimen has helped to increase patient ac-
ceptance and compliance with pharmaceutical ther-
apy.41 Ibandronate has been shown to offer similar
binding to bone and interactions with hydroxyapatite
as alendronate.42,43 In summary, alendronate slows
bone turnover, which allows secondary mineralization
to progress, increasing the tissue mineral content.
Alendronate therapy results in an increase in tissue
mineral content (mineral level divided by tissue vol-
ume), not bone mass (tissue volume divided by the to-
tal volume). As secondary mineralization continues,
there is an overall hypermineralization, which may
be more brittle and contribute to reduced fracture
toughness. In addition, the suppression of bone turn-
over inhibits the ability to repair bone microdamage,
which leads to an accumulation of microdamage.
Alendronate suppression of bone turnover produces
a 2% to 7% increase in bone microdamage accumula-
tion resulting in a 20% reduction in bone toughness.
There is no change in bone strength, only in tough-
ness, which is the ability to withstand deformation
without breaking.44
To date, there has been little in the literature regard-
ing the influence of the use of oral bisphosphonate on
bone healing. These drugs have now been in use for
>10 years, and the numbers of patients who have used
them or continue to use them are increasing. This re-
port reviews the implant-based therapy of a long-term
oral bisphosphonate user. In particular, treatment
modalities that were implemented successfully to
overcome unexpected complications in healing
post–implant placement are presented.
‡ Fosamax, Merck, Whitehouse Station, NJ.
§ Boniva, Roche Pharmaceutical, Nutley, NJ.
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CASE REPORT
The patient, a 65-year-old white woman, presented to
the faculty clinic on November 30, 2004, at the Univer-
sity of Michigan School of Dentistry (DFA) for implant
evaluation. The patient’s medical history was positive
forosteoporosisandarthritis;shealsoreportedahistory
of right hip fracture at age 55. The patient’s list of med-
ications included a calcium supplementk and oral
alendronate, which she later reported taking orally for
over 10 years. She had previously been taking conju-
gated estrogens¶ but discontinued. She had a history
ofsmokingbutquit>20yearsprior.Hematologic(com-
plete blood count) and urine analysis did not reveal any
abnormalities other than elevated cholesterol (216 mg/
dl, expected is <200 mg/dl) and low-density lipopro-
teins (134 mg/dl, expected is <100 mg/dl). Her bone
mineral density by dual x-ray absorptiometry over
the previous 10 years ranged from T scores of -1.6
to -1.9 for the vertebrae and -1.8 to -3.5 at the femur.
The patient’s chief complaint on presentation to the
university dental clinic was that of a fractured bridge
on the lower left, which she reported having occurred
during a recent biopsy procedure. A thorough clinical
examination was performed, leading to the following
diagnosis: generalized mild chronic periodontitis, gin-
gival recession, apical periodontitis on tooth #29,
mandibular partial edentulism with associated func-
tional deficit, and maxillary complete edentulism.
The treatment plan consisted of extraction of tooth
#29 and implants to replace teeth #18 through #20,
#29, and #30 for the correction of the mandibular
functional deficit associated with partial edentulism.
Tooth #29 was extracted by the referring general den-
tist, and the patient presented to DFA 2.5 months after
initial consultation.The healing of the extractionsocket
from tooth #29 appeared radiographically and clini-
cally to have progressed without any complications.
Alginate impressions were taken, and surgical guides
were fabricated to aid implant placement.
The patient presented 1 month after the mandibular
impression was taken for implant surgery. Five im-
plants# were placed into the patient’s mandible, three
on the left side replacing teeth #18 through #20 and
two implants on the right side replacing teeth #29 and
#30 (Figs. 1 through 4). The implant placement pro-
ceededwithout incident.Thesitewassutured toachieve
primary closure. Postoperative prescriptions consisted
of azithromycin,** 500 mg every day for 3 days, which
was started the day of surgery; 7.5 mg hydrocodone/
500 mg acetaminophen,†† 1 tablet every 4 to 6 hours
as needed for pain; and ibuprofen,‡‡ 400 to 600 mg as
needed every 4 to 6 hours. The patient was telephoned
later that same day and reported no complications.
Ten days after surgery, the patient returned for su-
ture removal and postoperative examination. Healing
Figure 1.
Occlusal view. Implants placed according to the surgical guides in the
area of teeth #18 through #20.
Figure 2.
Buccal view. Flap closure after bone graft.
Figure 3.
Radiograph shows good radiodensity surrounding three implants placed
(location: teeth #18 through #20). The x-ray was taken right after
implant placement.
k Caltrate D, Wyeth Pharmaceuticals, Madison, NJ.
¶ Premarin, Wyeth Pharmaceuticals.
# ITI Standard Plus, Straumann USA, Andover, MA.
** Zithromax, Pfizer, New York, NY.
†† Vicodin ES, Knoll Pharmaceuticals, Mount Olive, NJ.
‡‡ Advil, Wyeth Pharmaceuticals.
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appeared to be progressing rather uneventfully, and
the patient was scheduled for an additional postoper-
ative visit 4 weeks later. The patient returned to the
DFA 6 weeks after implant surgery with a fluctuant
swelling located in the buccal mucosa near implants
#19 and #20 (Fig. 5). A small needle puncture was
performed and revealed suppuration. A periapical
x-ray was taken of the area. The x-ray revealed radi-
olucency around the apex of implants #19 and #20
(Fig. 6). The site was locally anesthetized, and inci-
sion and drainage of the fluctuant mass were per-
formed. The site was irrigated with normal saline,
and the patient was placed on azithromycin, 500
mg every day for 3 days. The patient was scheduled
for surgery to evaluate and correct any osseous de-
fects surrounding the implants.
Roughly 1 week after incision and drainage, the pa-
tient returned to DFA for surgical evaluation of the
area of implants #18 through #20. The patient re-
ported a change in her osteoporosis medication from
oral alendronate to teriparatide§§ nearly 3 weeks be-
fore. Two periapical films were taken before surgery.
Radiolucencies were still evident around the apex of
implants #19 and #20. The additional periapical film
of the right side revealed a periapical radiolucency at
the apex of implant #29. Clinically, both implant sites
appeared to have healed sufficiently, and there were
no signs of suppuration. The decision was made to
surgically evaluate the implants on the lower left.
On flap reflection, two intrabony defects were found
(Fig. 7). One defect was located near the apex of im-
plant #18, and the other was found mesial to implant
#19. The areas were thoroughly degranulated, and
the bone was curetted and detoxified with tetracycline
(pH = 2 to 3). The bony defects were repaired with
mineralized human cancellous bonekkmixed with tet-
racycline solution (500 mg in 5 cc sterile water) and
covered with a collagen membrane¶¶ (Figs. 8 and
9). The flaps were replaced and sutured to achieve pri-
mary closure (Fig. 10). The patient received thorough
oral hygiene instructions and was placed on cepha-
lexin,## 500 mg four times a day for 14 days, and a
chlorhexidine*** rinse.
The patient returned 10 days later for a scheduled
postoperative appointment. Sutures were removed
and the surgical site was evaluated clinically. Healing
was progressing with minimum complications. A
small piece of necrotic lingual bone was noted be-
tween implants #19 and #20 but was not a source
of discomfort to the patient. This piece of necrotic
bone was gently removed with a cotton forceps
(Fig. 11). The area was then irrigated with chlorhexi-
dine 0.12%. The patient was instructed to rinse the
Figure 4.
Radiograph shows good radiodensity surrounding two implants placed
(location: teeth #29 and #30). The x-ray was taken right after implant
placement.
Figure 5.
Six weeks postoperative. Clinical buccal view showed teeth #19 and
#20 had swelling buccally as well as between implants. Pus
exacerbation was evident on probing on both sites.
Figure 6.
Six weeks postoperative. Radiograph shows radiolucency surrounding
implants #19 and #20.
§§ Forteo, Eli Lilly, Indianapolis, IN.
kk Puros, Zimmer Dental, Carlsbad, CA.
¶¶ Biomend, Zimmer Dental.
## Keflex, Eli Lilly, Indianapolis, IN.
*** Peridex, Zila Pharmaceuticals, Phoenix, AZ.
Effect of Long-Term Oral Bisphosphonates on Implant Wound Healing Volume 78 • Number 3
588
area with chlorhexidine 0.12% at home to keep the
area clean. The patient was given a prescription for
azithromycin, 500 mg every day for 3 days, to begin
immediately after completing the cephalexin.
Two weeks later the patient returned for a sched-
uled postoperative visit. Oral examination of the
surgical site revealed complete uneventful healing.
The patient reported that a small piece of bone se-
questered out after the last visit. Two periapical films
revealed an increased density of the previous radio-
lucent areas (Fig. 12). The patient returned 4 weeks
later for another scheduled visit (Fig. 13). Clinically,
the surgical area appeared to be completely healed.
Two additional periapical films were taken, revealing
continued healing of the previous radiolucencies.
The patient returned to DFA 6 months after the ini-
tial implant placement (Figs. 14 and 15). Two periap-
ical films were taken revealing a continued healing of
the apical radiolucencies around implants #19, #20,
and #29 (Fig. 16). At 1 year, 3 months after tempo-
rary prosthesis in function, radiograph demonstrated
bone fill and disappearance of radiolucency (Fig. 17).
Figure 7.
Seven weeks postoperative. Area was reflected and granulomatous
tissues were removed. A huge defect was noted on the buccal aspect
of implant #18. Furthermore, a deep (12 mm) pocket without bone
was also noted between implants #19 and # 20.
Figure 8.
After degranulation, area was detoxified with tetracycline solution and
then grafted with 4:1 ratio mixture of human mineralized cancellous
bone and tetracycline.
Figure 9.
The grafted site was then covered with collagen membrane to
facilitate proper healing.
Figure 10.
Occlusal view. Flap closure.
Figure 11.
Two weeks post-corrective surgery. A piece of necrotic bone was noted
between implants #19 and #20. It was gently removed using a cotton
forceps. Clinical picture shown after necrotic bone was removed.
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Clinical evaluation showed no evidence of any altered
healing, and the sites were deemed ready to progress
to the final prosthetic restoration.
DISCUSSION
The prevalence of osteoporosis rises with age; epide-
miologic studies indicate that bone loss arises after
the fourth or fifth decade in both men and women.45
Postmenopausal women are at particular risk for bone
loss. The National Osteoporosis Risk Assessment46
investigation reported 40% of 200,160 healthy post-
menopausal women had peripheral bone mineral
density denoting osteopenia, and 7% had scores that
correlated with osteoporosis.
A major concern regarding patients with osteopo-
rosis requiring implant placement is the possibility
that the disease modifies the quality of bone or its re-
generative capacity to an extent that osseointegration
is compromised. In human histologic studies,47 oste-
oporotic bone exhibits reduced mechanical strength,
altered trabecular architecture, decreased mineral
Figure 12.
Three months post-corrective surgery. Radiograph shows improved
bone radiodensity around implants #19 and #20.
Figure 13.
Four months postsurgery. Radiograph shows improved bone
radiodensity around implants #29 and #30.
Figure 14.
Six months post-corrective surgery. Clinical examination revealed
uneventful healing, and the abutments were torqued to 35 Ncm as
recommended by the manufacturer. No movement of implants was
found, suggesting the osseointegration was achieved in all implants.
Figure 15.
Six months post-corrective surgery. Radiograph shows improved bone
radiodensity around implants #19 and #20.
Figure 16.
Seven months postoperative surgery. Radiograph shows improved bone
radiodensity around implants #29 and #30.
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content, increased crystallinity, and increased carbo-
nate:phosphate ratios. The exact clinical significance
of these properties remains unclear. An examination
of dental clinical studies on this osteoporosis reveals
little effect of this disease on implant success, at least
in the lower jaw. Friberg et al.48 placed 70 implants in
the jaws of 14 patients with osteoporosis. This group
achieved ‡97% success in both maxilla and mandi-
ble after 3-year follow-up. These studies suggested
that osteoporosis, by itself, does not affect implant
success.
Minsk and Polson49 analyzed a total of 450 maxil-
lary and mandibular implants placed in 116 postmen-
opausal women aged >50 years and achieved an
overall success of 92%; all failures occurred around
the time of abutment connection. A retrospective
analysis by August et al.50 determined that mandibu-
lar implant failure rates did not vary between premen-
opausal and postmenopausal women; in contrast,
postmenopausal subjects had significantly more
maxillary implants fail than their premenopausal
counterparts. Although these studies did not mention
the patient’s osteoporosis status, this study implies
that postmenopause patients have a higher risk for
implant failure. One reason that contributes to this
high failure rate, as stated by authors,50 is that many
of these patients had developed osteoporosis.
To prevent future bone fracture, many patients are
taking bisphosphonates. Recent interest has focused
on patients taking IV bisphosphonates and the risk of
developing osteonecrosis.31,35,51-56 However, there
is limited information about how long-term usage of
oral bisphosphonates may pose a challenge to overall
bone healing, in particular, during implant therapy.
The use of bisphosphonates is extensive and there
are now patients who have been on oral bisphospho-
nates for >10 years. This case report illustrates a pa-
tient who developed a significant bone defect with
necrosis after proper implant placement. Although a
cause and effect relationship cannot be established,
the long-term use of oral bisphosphonates should be
considered a potential contributing factor. This raises
an important consideration while treating patients
who are under long-term care with oral bisphospho-
nates. Clearly, well-controlled studies are needed to
link or deny any potential association.
The bony defect was successfully treated with a
combination of systemic antibiotics, antimicrobial
mouthrinse, and proper local defect management.
The local defect management included thorough de-
bridement of defects, detoxification with tetracycline
solution, mixed bone graft with tetracycline (4:1 ra-
tio), and coverage with a collagen membrane. How-
ever, it is important to address that the usage of
membrane in this case may not serve its purpose be-
cause it increases the chance of exposing the flap,57
which may result in exposing bone to oral cavity. This
may explain why there was necrotic bone noted after
this treatment.
Another factor that should be considered in the pa-
tient’s response to treatment is the medication change
from the bisphosphonate to teriparatide. The patient’s
physician switched the patient from oral alendronate
to teriparatide. Teriparatide, unlike bisphosphonates or
estrogen, is a synthetic parathyroid hormone (PTH).
Teriparatide contains recombinant human PTH
(1-34), which has an identical sequence to the 34
N-terminal amino acids (the biologically active re-
gion) of the 84-amino acid human PTH. Teriparatide
is given once daily by injection and usually is taken for
a period of 18 months. The drug is prescribed for os-
teoporotic men and postmenopausal women at risk
for fracture and is the only pharmaceutical agent on
the market that is anabolic (versus antiresorptive) for
bone. PTH is an endocrine factor that plays a promi-
nent role in regulating bone turnover. PTH is produced
by the parathyroid glands in response to a reduction in
serum calcium. The mechanism of PTH, although not
completely understood, is by both catabolic and ana-
bolic influences on bone.58-63 The action of PTH on
bone resorption is thought to be by an indirect action
on osteoblasts. Osteoclast recruitment, differentia-
tion, and activation are regulated primarily through
the interaction of receptor activator of nuclear fac-
tor-kappa B ligand (RANKL) with its receptor RANK.
The interaction of RANKL on osteoblasts with RANK
on preosteoclasts leads to an increase in mature, ac-
tive osteoclasts. A decoy receptor, osteoprotegerin
(OPG), can bind to RANKL and block osteoclast
differentiation and activity. PTH alters the ratio of
OPG:RANKL.64,65 The continuous delivery of PTH
produces an increase in RANKL mRNA and decreases
the mRNA transcription of OPG.66 In contrast, the
Figure 17.
Twelve months post-corrective surgery. A temporary implant-supported
bridge was placed. Periapical radiograph shows continuing improvement
of bone radiodensity around implants #19 and #20.
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intermittent delivery of PTH leads to an early decrease
of RANKL mRNA and increase of OPG mRNA, and
over time, both level off.67 The continuous presence
of PTH by infusion results in bone loss, whereas the
pulsatile delivery of PTH stimulates an increase in
bone formation.68 Interestingly, a recent report sug-
gests that the risk of osteonecrosis with bisphospho-
nate use could be associated with a preexisting
metabolic condition of elevated serum PTH levels
and the subsequent development of hypocalcemia.69
Bisphosphonates have been reported to induce hy-
perparathyroidism and hypocalcemia.70,71 Elevated
PTH levels at the same time that the resorption-medi-
ated repair is inhibited may compromise the mineral-
ization repair of bone in a healing site. It is unclear how
the use of teriparatide impacts this, but patients on
oral alendronate do not have sustained elevated
PTH levels, nor do they typically have hypocalcemia,
so it is unlikely that its use would compromise the re-
pair status and, in contrast, its anabolic mode of action
may be beneficial.
CONCLUSIONS
It is important for clinicians to be aware of the potential
risk of treating patients who are under bisphospho-
nate treatment, either orally or by IV infusion. As
stated on the American Academy of Periodontology
website regarding bisphosphonates: ‘‘However, in
light of the precaution, periodontists are advised to
determine whether a patient is receiving IV bisphosph-
onate therapy. If so, invasive dental procedures
should be avoided unless absolutely necessary. Con-
versely, if a periodontist becomes aware that a patient
is going to be treated with IV bisphosphonates, any
needed invasive dentistry should, if possible, be per-
formed before the initiation of such treatment.’’72
Although this does not include the oral usage of
bisphosphonate, this case report suggests that the
practitioners should be aware of the potential risk of
long-term oral usage of bisphosphonates, because it
may possess some risk in certain patient populations.
Future studies in this area are certainly encouraged.
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